Eledon Pharmaceuticals, Inc. Fair Value Adjustment of Warrants
Eledon Pharmaceuticals, Inc. (ELDN) reported Fair Value Adjustment of Warrants of $9.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $9.62M.
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $18.96M.
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$10.53M, a 150.32% decline year-over-year.
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$564.00K.
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2025 was -$33.45M.
- Eledon Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2024 was -$30.90M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.62M 10-Q · filed 2026-08-13 | $28.59M 10-Q · filed 2026-08-13 | $18.05M derived: sum of 3 quarters · filed 2026-08-13 | $17.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $18.96M 10-Q · filed 2026-05-13 | $8.43M derived: sum of 2 quarters · filed 2026-05-13 | $7.87M derived: sum of 3 quarters · filed 2026-05-13 | -$4.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$11.10M derived: sum of 2 quarters · filed 2026-03-19 | -$23.39M derived: sum of 3 quarters · filed 2026-08-13 | -$33.45M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$564.00K 10-Q · filed 2025-11-14 | -$12.86M derived: sum of 2 quarters · filed 2026-08-13 | -$22.92M 10-Q · filed 2025-11-14 | -$1.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$12.29M 10-Q · filed 2026-08-13 | -$22.35M 10-Q · filed 2026-08-13 | -$1.42M derived: sum of 3 quarters · filed 2026-08-13 | -$97.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$10.06M 10-Q · filed 2026-05-13 | $10.87M derived: sum of 2 quarters · filed 2026-05-13 | -$85.57M derived: sum of 3 quarters · filed 2026-05-13 | -$54.30M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $20.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$75.51M derived: sum of 2 quarters · filed 2026-03-19 | -$44.24M derived: sum of 3 quarters · filed 2026-03-19 | -$30.90M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$96.44M 10-Q · filed 2025-11-14 | -$65.17M derived: sum of 2 quarters · filed 2025-11-14 | -$51.83M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $31.27M 10-Q · filed 2025-08-14 | $44.61M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |